A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Completed
- Conditions
- Cancer of the LungSquamous Cell CarcinomaNeoplasms, PulmonaryPulmonary CancerLung CancerNeoplasms, LungAdenocarcinomaLung NeoplasmsCancer of LungPulmonary Neoplasms
- Registration Number
- NCT02370303
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
- Detailed Description
The plan is to collect both blood and tumor samples from the patient's lung cancer in order to validate this technology in detecting circulating tumor cells. The investigators will also obtain a postoperative blood sample to see if there is a decrease in the overall circulating tumor cell measurement once the tumor has been surgically removed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Stage IB and above non-small cell lung cancer or metastatic lung cancer
- Age >18 years old
- Willing and able to consent to study
- No prior history of neoadjuvant therapy.
Exclusion Criteria
- Age <18 years old
- Unable to provide consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number and types of mutations in the primary tumor. Within 1 year Number and type of mutations detectable in the matched circulating tumor cell samples. Within 1 year
- Secondary Outcome Measures
Name Time Method Concordance of mutations detected by either method. Within 1 year
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States